OPKO Health, Inc. (NASDAQ:OPK) Forecasted to Post Q1 2022 Earnings of ($0.08) Per Share

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for shares of OPKO Health in a report issued on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft expects that the biotechnology company will earn ($0.08) per share for the quarter.

OPKO Health (NASDAQ:OPK – Get Rating) last announced its earnings results on Thursday, February 24th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). OPKO Health had a negative net margin of 1.70% and a negative return on equity of 1.75%. The company had revenue of $401.30 million for the quarter, compared to analyst estimates of $317.26 million. During the same quarter last year, the company posted $0.05 EPS. OPKO Health’s quarterly revenue was down 18.9% compared to the same quarter last year.

OPK has been the subject of several other reports. TheStreet lowered OPKO Health from a “c” rating to a “d+” rating in a report on Friday, February 25th. StockNews.com initiated coverage on OPKO Health in a research report on Thursday, March 31st. They set a “sell” rating for the company. Piper Sandler upped their price target on shares of OPKO Health from $5.00 to $6.00 in a research note on Tuesday, January 18th. Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Monday, January 24th. Finally, Zacks Investment Research downgraded OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a research note on Monday, January 24th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.25.

Shares of NASDAQ:OPK opened at $2.98 on Tuesday. OPKO Health has a 52-week low of $2.79 and a 52-week high of $5.25. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -59.59 and a beta of 1.86. The company has a quick ratio of 2.23, a current ratio of 2.49 and a debt-to-equity ratio of 0.11. The company has a 50 day moving average of $3.32 and a two-hundred day moving average of $3.75.

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction dated Friday, March 11th. The stock was bought at an average cost of $3.13 per share, with a total value of $313,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders acquired 1,585,000 shares of company stock valued at $4,849,400. Insiders own 41.47% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cornerstone Investment Partners LLC bought a new position in OPKO Health during the 4th quarter worth $267,000. Kestra Advisory Services LLC boosted its stake in OPKO Health by 37.4% during the 4th quarter. Kestra Advisory Services LLC now owns 41,336 shares of the biotechnology company’s stock valued at $199,000 after purchasing an additional 11,260 shares during the last quarter. Castle Rock Wealth Management LLC purchased a new position in shares of OPKO Health in the 4th quarter worth approximately $73,000. Metropolitan Life Insurance Co NY raised its holdings in shares of OPKO Health by 9.9% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 107,781 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 9,693 shares during the period. Finally, Rafferty Asset Management LLC raised its holdings in OPKO Health by 24.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 870,666 shares of the biotechnology company’s stock valued at $3,178,000 after acquiring an additional 169,452 shares during the period. Institutional investors own 26.34% of the company’s stock.

OPKO Health Company Profile (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Featured Stories